NasdaqGS:GILDBiotechs
Gilead’s Arcellx Deal And HIV Data Reframe Growth And Valuation Story
Gilead Sciences (NasdaqGS:GILD) has agreed to acquire Arcellx in a $7.8b deal, expanding its presence in cell therapies for blood cancers.
The acquisition adds a near-approval CAR T cell therapy candidate to Gilead’s oncology portfolio.
Separately, Gilead reported new Phase 3 data for an investigational once daily, single tablet HIV regimen, showing noninferior efficacy and high tolerability versus existing treatments.
For investors watching Gilead Sciences at a share price of $147.12,...